Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ultrasensitive Detection of Neurofilament Light in Plasma Using F(Ab')<sub>2</sub>-Modified Graphene Field-Effect Biosensor.

Small (Weinheim an der Bergstrasse, Germany)·2026

Same author

Deep learning for stenotic nares classification in brachycephalic dogs.

Veterinary research communications·2026

Same author

A Comparison of Four Selected Acoustic Measures in Detecting Voice Quality Changes With Botulinum Toxin Treatment in Adductor-Type Laryngeal Dystonia.

American journal of speech-language pathology·2026

Same author

Specific detection of Salmonella Typhi by probe-free quantitative polymerase chain reaction.

Archives of microbiology·2026

Same author

Klebsiella pneumoniae Invasive Syndrome without Liver Abscess: A Case Report.

The American journal of case reports·2025

Same author

CKS2 is overexpressed in high-grade and recurrent meningiomas and functions as an oncogene via the CKS2/miR-26a/miR-101 axis.

Computers in biology and medicine·2025

Same journal

Role of Cholesterol Metabolism in the Link Between Diabetes and Alzheimer's Disease.

CNS & neurological disorders drug targets·2026

Same journal

Linking Neurodegeneration and Age-related Macular Degeneration: Unified Pathways and Intervention Strategies.

CNS & neurological disorders drug targets·2026

Same journal

Modulating the Microbiota-gut-brain Axis: A Promising Strategy for Alzheimer's Disease Prevention and Management.

CNS & neurological disorders drug targets·2026

Same journal

The Therapeutic Effects of Dietary Supplements on OCD: A Narrative Review.

CNS & neurological disorders drug targets·2026

Same journal

Amyotrophic Lateral Sclerosis: Therapeutic Innovations and Evolving Regulatory Approaches.

CNS & neurological disorders drug targets·2026

Same journal

Pathogenic Proteins Driving ALS Pathogenesis: Molecular Mechanisms and Translational Therapeutic Perspectives.

CNS & neurological disorders drug targets·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Oct 21, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Immunotherapeutics for AD: A Work in Progress.

Anuja Sharma¹, Jaspreet Singh Anand², Yatender Kumar¹

¹Department of Biological Sciences and Engineering (BSE), Netaji Subhas University of Technology (NSUT), New Delhi, 110078, India.

CNS & Neurological Disorders Drug Targets

|September 3, 2021

Summary

This summary is machine-generated.

Alzheimer's Disease (AD) lacks effective treatments. This review explores immunotherapies targeting Amyloid-beta and Tau proteins, focusing on Tau

Keywords:

Alzheimer's Disease (AD)NFTs amyloid-β brain atrophy immunotherapy tau

More Related Videos

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Related Experiment Videos

Last Updated: Oct 21, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Area of Science:

Neuroscience
Immunology
Pharmacology

Background:

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder with no current cure.
Disease onset involves complex factors, beginning decades before clinical symptoms.
Existing therapies are insufficient for controlling or reversing AD progression.

Purpose of the Study:

To review active and passive immunotherapies for Alzheimer's Disease.
To analyze therapeutic strategies targeting Amyloid-beta (Aβ) and Tau proteins.
To highlight the focus on extracellular Tau targeting for preventing neurofibrillary tangle spread.

Main Methods:

Comprehensive literature review of existing and prospective immunotherapies for AD.
Analysis of therapeutic targets, including Amyloid-beta plaques and Tau protein.
Evaluation of strategies targeting extracellular Tau to inhibit seeding and propagation.

Main Results:

Several immunotherapies targeting Aβ plaques have faced challenges and failed.
Research is increasingly focusing on Tau protein as a therapeutic target.
Targeting extracellular Tau, particularly its mid-region, shows promise in preventing NFT spread.

Conclusions:

Immunotherapy remains a key research area for Alzheimer's Disease.
Targeting Tau protein, especially extracellular forms, offers a promising avenue.
Further understanding of AD mechanisms is crucial for developing effective treatments.